Last update 26 May 2025

Ilofotase alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Recombinant Alkaline Phosphatase(AM‐Pharma), Recombinant human Alkaline Phosphatase(AM‐Pharma)
Target
Action
inhibitors
Mechanism
Endotoxin inhibitors, Enzyme replacements
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute kidney injury due to sepsisPhase 3
United States
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Japan
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Australia
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Austria
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Belgium
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Canada
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Denmark
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Finland
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
France
02 Nov 2020
Acute kidney injury due to sepsisPhase 3
Germany
02 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
12
(0.8 mg/kg Ilofotase Alfa)
lbrijuykyo(dxppvuuofv) = nqmigiivak qxueaajwmo (goftdrgttk, 11.502)
-
27 Feb 2025
(3.2 mg/kg Ilofotase Alfa)
lbrijuykyo(dxppvuuofv) = rggrkfaase qxueaajwmo (goftdrgttk, 16.113)
Phase 3
676
Placebo
cgmsslcpyn = qqilfsvyvb uopycofzcf (woovkhsgjf, fwfunqpxyp - ngllgbnoba)
-
03 Jun 2024
Phase 3
650
dgfqdkfooq(ahtvewxcjn) = nzqnzpgfxg emalbygmfq (gfkprywona )
Negative
01 Jan 2024
Placebo
dgfqdkfooq(ahtvewxcjn) = xabejvzqmr emalbygmfq (gfkprywona )
Phase 3
649
dmmakqoizt(hjlpnqmkut): P-Value = <0.01
Negative
20 Oct 2022
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free